This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Enhabit (EHAB) Hisse Özeti
Enhabit, Inc. Amerika Birleşik Devletleri'nde evde sağlık ve darülaceze hizmetleri sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 5/6 |
| Gelecekteki Büyüme | 3/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 3/6 |
| Temettüler | 0/6 |
EHAB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Enhabit, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$13.80 |
| 52 Haftanın En Yüksek Seviyesi | US$14.22 |
| 52 Haftanın En Düşük Seviyesi | US$6.47 |
| Beta | 0.96 |
| 1 Aylık Değişim | 0.51% |
| 3 Aylık Değişim | 23.66% |
| 1 Yıllık Değişim | 29.70% |
| 3 Yıllık Değişim | 16.06% |
| 5 Yıllık Değişim | n/a |
| Halka arzdan bu yana değişim | -44.80% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Apr 24
EHAB: Kinderhook Cash Offer And Deal Completion Will Shape Forward Risk Balance
Analysts have aligned Enhabit’s updated fair value estimate with the agreed Kinderhook Industries takeout price, trimming the target by $0.03 to $13.80 as they factor in the all cash $13.80 per share acquisition and modest tweaks to growth, margin and discount rate assumptions. Analyst Commentary Street research has largely converged around Enhabit’s agreed takeout price, with multiple firms resetting ratings and targets to align with the US$13.80 per share all cash offer from Kinderhook Industries.Anlatı Güncellemesi • Apr 10
EHAB: Cash Sale Terms And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have inched their average price target for Enhabit up by about $0.03 to roughly $13.83, reflecting recent research that aligns estimates with the agreed all cash acquisition price of $13.80 per share. Analyst Commentary Recent research on Enhabit has shifted quickly after the announced all cash acquisition at $13.80 per share, with most commentary now centered on how closely the stock aligns with the agreed deal value rather than on long term standalone upside.Anlatı Güncellemesi • Mar 26
EHAB: Kinderhook Cash Deal And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have adjusted Enhabit’s price target to $13.80 per share, in line with the agreed all cash acquisition price from Kinderhook Industries. They cite the pending takeout and recent shifts in ratings to Hold, Neutral, Perform and Market Perform at multiple firms as the key drivers of this update.Recent updates
Anlatı Güncellemesi • Apr 24
EHAB: Kinderhook Cash Offer And Deal Completion Will Shape Forward Risk Balance
Analysts have aligned Enhabit’s updated fair value estimate with the agreed Kinderhook Industries takeout price, trimming the target by $0.03 to $13.80 as they factor in the all cash $13.80 per share acquisition and modest tweaks to growth, margin and discount rate assumptions. Analyst Commentary Street research has largely converged around Enhabit’s agreed takeout price, with multiple firms resetting ratings and targets to align with the US$13.80 per share all cash offer from Kinderhook Industries.Anlatı Güncellemesi • Apr 10
EHAB: Cash Sale Terms And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have inched their average price target for Enhabit up by about $0.03 to roughly $13.83, reflecting recent research that aligns estimates with the agreed all cash acquisition price of $13.80 per share. Analyst Commentary Recent research on Enhabit has shifted quickly after the announced all cash acquisition at $13.80 per share, with most commentary now centered on how closely the stock aligns with the agreed deal value rather than on long term standalone upside.Anlatı Güncellemesi • Mar 26
EHAB: Kinderhook Cash Deal And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have adjusted Enhabit’s price target to $13.80 per share, in line with the agreed all cash acquisition price from Kinderhook Industries. They cite the pending takeout and recent shifts in ratings to Hold, Neutral, Perform and Market Perform at multiple firms as the key drivers of this update.Anlatı Güncellemesi • Mar 10
EHAB: Kinderhook Cash Takeout And Sector Reimbursement Trends Will Shape Forward Risk Balance
The analyst price target for Enhabit has been adjusted from $13.08 to $13.80. Analysts cite the agreed all-cash acquisition by Kinderhook Industries at $13.80 per share as the primary reference point for the valuation.Seeking Alpha • Feb 25
Enhabit: Why This Healthcare Buyout Won't Raise FTC Alarms
Summary Enhabit Inc. is being acquired by Kinderhook Industries for $13.80 per share, an all-cash deal at an enterprise valuation of $1.1 billion. I see minimal antitrust risk, as Kinderhook lacks significant overlap in hospice care, making regulatory intervention unlikely. EHAB trades at a discount to peers due to higher debt and inconsistent profitability, but the acquisition premium reflects limited market optimism. With only a 1.8% spread to the deal price and limited upside, I rate EHAB a Hold pending deal completion. Read the full article on Seeking AlphaAnlatı Güncellemesi • Feb 24
EHAB: Takeout At 13.80 And Reimbursement Clarity Will Shape Forward Risk Balance
The analyst price target for Enhabit has been raised from $11.75 to $13.08. Analysts cited the agreed all-cash acquisition at $13.80 per share and related updates to assumed future P/E as the key drivers of the change.Anlatı Güncellemesi • Feb 08
EHAB: Clearer Reimbursement And Mixed Ratings Will Shape Forward Risk Balance
Narrative Update on Enhabit The analyst price target for Enhabit has moved to $11.75. Analysts note that clearer home health reimbursement rules, an improved regulatory backdrop, and what they describe as a discounted valuation support a more constructive stance on the shares.Anlatı Güncellemesi • Jan 25
EHAB: Clearer Reimbursement And Mixed Ratings Will Shape Future Earnings Visibility
Narrative Update The analyst price target for Enhabit has shifted from $10.60 to $11.75, as analysts factor in an improved home health reimbursement backdrop, clearer earnings visibility, and reduced regulatory overhang reflected in recent upgrades and higher targets around $12. Analyst Commentary Recent research on Enhabit has turned more positive, with several firms lifting ratings and price targets to around US$12 as the regulatory picture for home health reimbursement becomes clearer.Anlatı Güncellemesi • Jan 10
EHAB: Final Rule Clarity And Mixed Ratings Will Shape Earnings Outlook
Analysts have lifted their price expectations for Enhabit, with our fair value estimate moving from US$9.38 to US$10.60. They point to greater earnings clarity following the final home health rule, a modest adjustment to discount rates and profit assumptions, and recent research that highlights both improving operations and what some see as a discounted valuation.Anlatı Güncellemesi • Aug 08
Aging Demographics Will Fuel US Home Care Expansion
Despite a notable improvement in net profit margin and a lower future P/E ratio, the consensus analyst price target for Enhabit has been reduced from $10.00 to $9.38. What's in the News Enhabit, Inc.Analiz Makalesi • Jul 03
Enhabit, Inc. (NYSE:EHAB) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Enhabit, Inc. ( NYSE:EHAB ) shareholders won't be pleased to see that the share price has had a very rough month...Analiz Makalesi • Jun 14
Enhabit (NYSE:EHAB) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Yeni Anlatı • May 29
US Home Health Demand And Value-Based Care Will Create Future Opportunities
Structural trends and targeted expansion in underserved markets are driving sustained revenue growth and building a reliable recurring revenue base.Analiz Makalesi • May 09
Returns On Capital At Enhabit (NYSE:EHAB) Paint A Concerning Picture
When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...Analiz Makalesi • Apr 09
Enhabit, Inc.'s (NYSE:EHAB) Revenues Are Not Doing Enough For Some Investors
When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...Seeking Alpha • Feb 03
Enhabit: Healthcare Predictive Analytics, FCF, Very Undervalued
Summary EHAB's investments in healthcare predictive analytics, expected to grow at 23%-24% CAGR, could significantly boost future net income growth. Restructuring, activism, and strategic reviews are potential catalysts for stock price appreciation, enhancing financial flexibility from 2025 to 2030. Despite recent negative net income, EHAB's consistent positive cash flow and undervaluation indicate substantial upside potential in stock price. Valuation models suggest higher upside potential, with best case scenario implying a target price of $11-$12 per share. Read the full article on Seeking AlphaAnaliz Makalesi • Dec 14
Is Enhabit (NYSE:EHAB) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • Nov 07
Returns On Capital At Enhabit (NYSE:EHAB) Paint A Concerning Picture
If you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...Analiz Makalesi • Jul 17
Is Enhabit (NYSE:EHAB) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Jul 15
Is Enhabit Dead? Not Quite Yet
Summary It is soon to be the last independent home health and hospice company. Scarcity value could drive interest from financial and strategic bidders. Shareholders have a slate of new directors to refresh the company. Read the full article on Seeking AlphaAnaliz Makalesi • Jun 19
Enhabit (NYSE:EHAB) Could Be At Risk Of Shrinking As A Company
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...Analiz Makalesi • May 10
An Intrinsic Calculation For Enhabit, Inc. (NYSE:EHAB) Suggests It's 42% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Enhabit fair value estimate is US$14.19 Enhabit is estimated...Analiz Makalesi • Mar 09
Here's What Analysts Are Forecasting For Enhabit, Inc. (NYSE:EHAB) After Its Annual Results
It's been a pretty great week for Enhabit, Inc. ( NYSE:EHAB ) shareholders, with its shares surging 17% to US$10.34 in...Analiz Makalesi • Mar 05
The Market Doesn't Like What It Sees From Enhabit, Inc.'s (NYSE:EHAB) Revenues Yet
You may think that with a price-to-sales (or "P/S") ratio of 0.4x Enhabit, Inc. ( NYSE:EHAB ) is a stock worth checking...Analiz Makalesi • Feb 09
Enhabit (NYSE:EHAB) Could Be Struggling To Allocate Capital
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...Hissedar Getirileri
| EHAB | US Healthcare | US Pazar | |
|---|---|---|---|
| 7D | 0.07% | -0.6% | 2.2% |
| 1Y | 29.7% | 40.5% | 20.9% |
Getiri vs. Endüstri: EHAB geçen yıl % 40.5 oranında getiri sağlayan US Healthcare sektörünü aştı.
Getiri vs Piyasa: EHAB geçen yıl % 20.9 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| EHAB volatility | |
|---|---|
| EHAB Average Weekly Movement | 6.6% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: EHAB son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: EHAB 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1998 | 10,800 | Barb Jacobsmeyer | www.ehab.com |
Enhabit, Inc. Amerika Birleşik Devletleri'nde evde sağlık ve hospis hizmetleri sunmaktadır. Evde Sağlık segmenti hemşirelik bakımı; fiziksel, mesleki ve konuşma terapisi; tıbbi ve sosyal hizmet; ve evde sağlık yardımcısı hizmetleri sunmaktadır. Bu segment ayrıca hasta eğitimi, ağrı yönetimi, yara bakımı ve pansuman değişiklikleri, kardiyak rehabilitasyon, infüzyon tedavisi, ilaç yönetimi ve vasıflı gözlem ve değerlendirme hizmetleri de sunmaktadır; diyabet, hipertansiyon, artrit, Alzheimer hastalığı, az görme, spinal stenoz, Parkinson hastalığı, osteoporoz, kompleks yara bakımı ve kronik ağrı gibi kronik hastalık ve durumların tedavisine yönelik uygulamalar ile diyabet, konjestif kalp yetmezliği, ortopedik cerrahi veya yaralanma sonrası ve solunum yolu hastalıkları olan hastalar için hastalığa özel planlar; ve bir hastanın sağlıkla ilgili sorunlarından kaynaklanan mali, kişisel ve sosyal kaygılar konusunda hastalar ve aileleri için danışmanlık.
Enhabit, Inc. Temel Bilgiler Özeti
| EHAB temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$706.91m |
| Kazançlar(TTM) | -US$3.20m |
| Gelir(TTM) | US$1.06b |
0.7x
P/S Oranı-220.9x
F/K OranıEHAB aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| EHAB gelir tablosu (TTM) | |
|---|---|
| Gelir | US$1.06b |
| Gelir Maliyeti | US$544.20m |
| Brüt Kâr | US$520.70m |
| Diğer Giderler | US$523.90m |
| Kazançlar | -US$3.20m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.062 |
| Brüt Marj | 48.90% |
| Net Kâr Marjı | -0.30% |
| Borç/Özkaynak Oranı | 72.7% |
EHAB uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/16 02:37 |
| Gün Sonu Hisse Fiyatı | 2026/05/14 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Enhabit, Inc. 5 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Joanna Sylvia Gajuk | BofA Global Research |
| Jason Cassorla | Citigroup Inc |
| Jamie Perse | Goldman Sachs |